US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

1.32

-0.0200-1.49%

Volume:181.79K

Turnover:241.17K

Market Cap:242.74M

PE:-6.44

High:1.36

Open:1.30

Low:1.28

Close:1.34

Loading ...

Overview Company News Filings

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility

MT Newswires Live

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

THOMSON REUTERS

Press Release: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen announces Tevogen Generics following Trump’s tariff-related statements

Tevogen Bio Holdings: Announces Newest Effort, Tevogen Generics

THOMSON REUTERS

Tevogen Bio Holdings: Initiative Seeks to Expedite Domestic Manufacturing of Unbranded Pharmaceuticals & Apis in US

THOMSON REUTERS

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

Tevogen Bio Holdings Delays Annual Report Filing

Press Release: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Tevogen Bio Files New US Patent for T Cell Vaccine Under Development

MT Newswires Live

BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO

Tevogen announces new patent filed for T cell vaccine

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto

THOMSON REUTERS

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TVGN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":1.32,"timestamp":1749741266140,"preClose":1.34,"halted":0,"volume":181791,"delay":0,"floatShares":18880265,"shares":183893433,"eps":-0.204889,"marketStatus":"Trading","change":-0.02,"latestTime":"06-12 11:15:01 EDT","open":1.3,"high":1.355,"low":1.282,"amount":241172.7029262,"amplitude":0.054478,"askPrice":1.33,"askSize":635,"bidPrice":1.32,"bidSize":532,"shortable":3,"etf":0,"ttmEps":-0.204889,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749758400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.34,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.34,"latestTime":"09:02 EDT","volume":1984,"amount":2628.5309696,"timestamp":1749733375355},"postHourTrading":{"tag":"盘后","latestPrice":1.3117,"preClose":1.34,"latestTime":"19:59 EDT","volume":5981,"amount":7912.5185,"timestamp":1749686377525},"volumeRatio":0.459779},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":18880265,"roa":"-578.29%","roe":"--","lyrEps":-0.070045,"volumeRatio":0.459779,"shares":183893433,"dividePrice":0,"high":1.355,"amplitude":0.054478,"preClose":1.34,"low":1.282,"week52Low":0.2556,"pbRate":"-14.69","week52High":3.09,"institutionHeld":0,"latestPrice":1.32,"committee":-0.08826,"eps":-0.204889,"divideRate":0,"volume":181791,"delay":0,"ttmEps":-0.204889,"open":1.3,"prevYearClose":1.03,"prevWeekClose":1.43,"prevMonthClose":1.29,"prevQuarterClose":1.08,"fiveDayClose":1.41,"twentyDayClose":1.1,"sixtyDayClose":1.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531261385","title":"Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2531261385","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531261385?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:36","pubTimestamp":1745872560,"startTime":"0","endTime":"0","summary":"Reflects business philosophy of commercial success through patient accessibility. Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity. WARREN, N.J., April 28, 2025  -- Tevogen  , reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-reaffirms-oncology-top-line-203600841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN"],"gpt_icon":0},{"id":"2530169399","title":"Tevogen Bio Announces 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530169399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530169399?lang=en_us&edition=fundamental","pubTime":"2025-04-26 02:33","pubTimestamp":1745605980,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 25, 2025  -- Tevogen Bio Holdings Inc.   today announced that the Company will hold its 2025 annual meeting of stockholders  via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company’s independent registered public accounting firm.Tevogen Bio encourages all stockholders of record as of April 30, 2025, to participate in this year’s vote. Proxy materials, including detailed instructions for voting, will be distributed or made available in accordance with Securities and Exchange Commission  regulations to stockholders of record as of April 30, 2025. If you are a stockholder and provide your 16-digit control number, which can be found on your Notice of Internet Availability, proxy card, or voting instruction form, you will be able to vote your shares at the Annual Meeting.The Company intends to disclose the Annual","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-2025-annual-183300444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2529038388","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529038388","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529038388?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:06","pubTimestamp":1745237160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 08:06 ET (12:06 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2528778487","title":"Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528778487","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528778487?lang=en_us&edition=fundamental","pubTime":"2025-04-18 03:50","pubTimestamp":1744919432,"startTime":"0","endTime":"0","summary":"Tevogen Bio  said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.Shares of the company were down about 4.9% in recent trading.Price: 0.97, Change: -0.05, Percent Change: -4.80","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2528727132","title":"Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528727132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528727132?lang=en_us&edition=fundamental","pubTime":"2025-04-18 02:55","pubTimestamp":1744916108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV39D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2528153727","title":"Press Release: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528153727","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528153727?lang=en_us&edition=fundamental","pubTime":"2025-04-18 02:54","pubTimestamp":1744916040,"startTime":"0","endTime":"0","summary":"-- The agreement would facilitate providing Tevogen Bio with in-house cell. -- Formalized agreement aligns with previously announced topline forecasts. This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; Tevogen's ability to build GMP capabilities at scale; the prospective benefits of the agreement with CD8; expectations regarding future product revenues; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as \"may,\" \"could,\" \"would,\" \"expect,\" \"anticipate,\" \"possible,\" \"potential, \" \"goal,\" \"opportunity,\" \"project,\" \"believe,\" \"future,\" and similar words and expressions or their opposites. These statements are based on","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2527298664","title":"Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction","url":"https://stock-news.laohu8.com/highlight/detail?id=2527298664","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527298664?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:03","pubTimestamp":1744740180,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 15, 2025  -- Tevogen  , today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence , with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy.Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. This support should advance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor  engagement with those complexes. The efforts will be directed to bring two foundational models to bear based on the company’s revolutionary ExacTcellplatform: predicting immunologically active peptides through machine learning and developing a predictive T cell receptor binding model.This announcement marks the third foundational support pillar for Tevogen.AI, the Company’s AI initiative which aims to transform precisi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-commissions-databricks-accelerate-180300735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","AAQC"],"gpt_icon":0},{"id":"2527111133","title":"Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2527111133","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527111133?lang=en_us&edition=fundamental","pubTime":"2025-04-15 01:53","pubTimestamp":1744653180,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 14, 2025  -- Tevogen  , today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-ceo-join-dialogue-paths-175300708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW"],"gpt_icon":0},{"id":"2526910312","title":"Tevogen announces Tevogen Generics following Trump’s tariff-related statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526910312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526910312?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:55","pubTimestamp":1744224909,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced its newest effort: Tevogen Generics. “This effort is in response to the growing national focus on pharmaceutical affordabi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-tevogen-generics-following-trumps-tariff-related-statements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-tevogen-generics-following-trumps-tariff-related-statements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2526128363","title":"Tevogen Bio Holdings: Announces Newest Effort, Tevogen Generics","url":"https://stock-news.laohu8.com/highlight/detail?id=2526128363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526128363?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:46","pubTimestamp":1744224393,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2526031289","title":"Tevogen Bio Holdings: Initiative Seeks to Expedite Domestic Manufacturing of Unbranded Pharmaceuticals & Apis in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2526031289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526031289?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:46","pubTimestamp":1744224393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1AF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2525798450","title":"Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission","url":"https://stock-news.laohu8.com/highlight/detail?id=2525798450","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525798450?lang=en_us&edition=fundamental","pubTime":"2025-04-08 03:58","pubTimestamp":1744055880,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 07, 2025  -- Tevogen  , a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, is unified by a commitment to advancing patient-centric solutions. The Company’s clinical-stage immunotherapy effort, Tevogen Bio, focuses on the development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. Its artificial intelligence effort, Tevogen.AI, aims to advance innovation in drug discovery, clinical trial efficiency, and patient access. Together, these efforts represent the foundational pillars of Tevogen’s broader vision to redefine the future of medicine.With this in mind, Tevogen today highlights the significant number of shares held by executive officers and members of the board of directors of the Company, emphasizing their conviction of the mission and progress of Tevogen. The insiders own approximately 74% of the outstanding shares, a unique advantage as compared to other similar companies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-highlights-most-recent-195800476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":1},{"id":"2524447148","title":"Tevogen Bio Holdings Delays Annual Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524447148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524447148?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:21","pubTimestamp":1743517301,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings ( ($TVGN) ) has released a notification of late filing. Tevogen Bio Holdings Inc. has announced a delay in filing its Form 10-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-delays-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-delays-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2522889098","title":"Press Release: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522889098","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522889098?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:11","pubTimestamp":1742922660,"startTime":"0","endTime":"0","summary":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan. WARREN, N.J., March 25, 2025  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the c","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1244550494.USD","LU0912757837.SGD","LU2430703178.SGD","JNJ","LU1894683264.USD","IE0002270589.USD","LU0795875169.SGD","SG9999001440.SGD","LU1261432733.SGD","LU1023059063.AUD","BK4559","LU0203347892.USD","LU2430703251.USD","LU2505996509.AUD","IE00B42XCP33.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU2505996681.GBP","IE000M9KFDE8.USD","IE0009355771.USD","IE00B3PB1722.GBP","BK4585","LU2592432038.USD","BK4139","LU0098860793.USD","BK4504","LU1267930813.SGD","SG9999002232.USD","BK4581","BK4588","LU0795875086.SGD","LU2468319806.SGD","IE00BVYPNW00.USD","LU0114720955.EUR","LU0203345920.USD","IE0034235303.USD","TVGN","LU1585245621.USD","LU1430594728.SGD","IE00B1BXHZ80.USD","LU0792757196.USD","LU1244550577.SGD","LU0466842654.USD","LU1718418525.SGD","LU2112291526.USD","LU2129689514.USD","LU1066051811.HKD","LU1221951129.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2518717860","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518717860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518717860?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:20","pubTimestamp":1741692000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 07:20 ET (11:20 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2518208702","title":"Tevogen Bio Files New US Patent for T Cell Vaccine Under Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208702","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208702?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:18","pubTimestamp":1741627092,"startTime":"0","endTime":"0","summary":"Tevogen Bio  said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development.The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines that mainly induce a B cell response.Tevogen Bio said that similar to its lead product candidate TVGN 489, the vaccine can target the entire viral genome, helping to mitigate a risk posed by mutations.The company's shares were down over 5% in recent trading.Price: 1.08, Change: -0.06, Percent Change: -5.09","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2518208975","title":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208975?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:06","pubTimestamp":1741626362,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTOMarch 10 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO ANNOUNCES UNIQUE T CELL VACCINE UNDER DEVE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2518203871","title":"Tevogen announces new patent filed for T cell vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2518203871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518203871?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:45","pubTimestamp":1741625135,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) Bio announced the filing of a new patent with the U.S. Patent and Trademark Office for its under-development T cell vaccine. “Unlike...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-new-patent-filed-for-t-cell-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-new-patent-filed-for-t-cell-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2518270844","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2518270671","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270671","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270671?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624800,"startTime":"0","endTime":"0","summary":"Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibilit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-unique-t-164000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"TVGN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-06-11","current":-6.448882,"percent":0.849673,"low":-87.683882,"twenty":-32.068526,"median":-17.766767,"eighty":-7.138439,"high":-2.106753,"avg":-21.636737,"sd":15.948729,"marketCap":228027856},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367},{"date":"2025-05-02","current":-13.10675,"twenty":-32.74034,"median":-21.917772,"eighty":-7.830197,"marketCap":179921334},{"date":"2025-05-09","current":-14.601755,"twenty":-32.722315,"median":-21.231576,"eighty":-7.830197,"marketCap":200443841},{"date":"2025-05-16","current":-5.980818,"twenty":-32.552659,"median":-20.228412,"eighty":-7.830197,"marketCap":211477447},{"date":"2025-05-23","current":-6.396875,"twenty":-32.510851,"median":-19.566511,"eighty":-7.465051,"marketCap":226188922},{"date":"2025-05-30","current":-6.968954,"twenty":-32.378153,"median":-18.686729,"eighty":-7.414206,"marketCap":246417200},{"date":"2025-06-06","current":-7.333003,"twenty":-32.156991,"median":-18.297627,"eighty":-7.218412,"marketCap":259289740},{"date":"2025-06-11","current":-6.448882,"twenty":-32.068526,"median":-17.766767,"eighty":-7.138439,"marketCap":228027856}],"updateTime":1749732351478}}}